Group 1 - Bid Pharma executed two block trades on November 28, totaling 180,900 shares and a transaction value of 11.0349 million yuan, with a transaction price of 61.00 yuan, representing a discount of 16.15% compared to the closing price of the day [2][3] - Over the past three months, Bid Pharma has recorded a total of nine block trades, amounting to 47.5363 million yuan [2] - The closing price of Bid Pharma on the same day was 72.75 yuan, reflecting an increase of 0.64%, with a daily turnover rate of 1.09% and a total transaction amount of 34.0668 million yuan, resulting in a net inflow of 1.9562 million yuan in main funds [2] Group 2 - The latest margin financing balance for Bid Pharma is 31.8630 million yuan, which has increased by 0.8313 million yuan over the past five days, marking a growth rate of 2.68% [3] - Bid Pharma was established on April 27, 2007, with a registered capital of 90.882948 million yuan [3]

Policy Developments - The National Health Commission will hold a press conference on November 27, 2025, to discuss the progress and effectiveness of grassroots medical and health services [1] Industry Initiatives - Beijing's Economic and Information Technology Bureau, along with six departments, has introduced measures to accelerate the promotion of artificial intelligence-assisted diagnostic technologies, including financial support of up to 50 million yuan for selected projects [2] Regulatory Approvals - Saikexide has obtained registration for three medical device products, enhancing its product range in the in vitro diagnostic field [3] - Xinhua Pharmaceutical has received a drug registration certificate for a compound local anesthetic cream, with an estimated sales revenue of 615 million yuan in 2024 [4] - Heng Rui Medicine has received approval for clinical trials of its innovative anti-tumor drug HRS-8364, with a cumulative R&D investment of approximately 21.65 million yuan [5] Capital Market Activities - Suzhou High-tech plans to sell a 47% stake in its medical device subsidiary for 604 million yuan [6] - Shanghai DeYin Technology has completed a Pre-A round financing of several million yuan, backed by listed company Songlin Technology [8] Industry News - Novartis China has responded to rumors of dissolving its county-level team, stating it will adjust its operational model while continuing to serve the county medical market [9] - Samsung Medical's subsidiary has been recommended as a candidate for a procurement project with a total expected amount of approximately 107 million yuan [10] Legal Matters - Foreign companies have filed a Section 337 investigation request against specific antibody-drug conjugates, alleging infringement of trade secrets, involving companies from the US, Netherlands, and China [11] Shareholder Actions - Bid Pharma's shareholder plans to reduce their stake by up to 0.16% between December 17, 2025, and March 16, 2026, due to funding needs [12]

Core Viewpoint - Multiple companies are announcing share reductions by major shareholders, indicating potential shifts in ownership and investor sentiment in the market [1] Shareholder Reductions - Zhongfu Shenying: Eagle Group plans to reduce its stake by no more than 1% [1] - Luxiao Technology: Actual controller and concerted parties plan to reduce their stake by no more than 3% [1] - Chenxi Aviation: Controlling shareholder intends to reduce its stake by no more than 3% [1] - Zhongchen Co., Ltd.: Controlling shareholder plans to reduce its stake by no more than 3% [1] - HeMai Co.: Shareholders Gangzhi Investment and Han Hualong plan to collectively reduce their stake by no more than 3% [1] - Kaipu Testing: General Manager Li Yaping intends to reduce her stake by no more than 1% [1] - Bide Pharmaceutical: Chairman and General Manager Dai Lan plans to reduce his stake by no more than 148,800 shares [1] - Jinhongshun: Gaode Investment has completed the reduction of 4.1556 million shares [1] - Buke Co.: Controlling shareholder Shanghai Bujin has cumulatively reduced its stake by 0.94% [1] - Andeli: Controlling shareholder has reduced its stake by 0.54% [1] - Hongbai New Materials: Controlling shareholder Hongbai Chemical has reduced 7.1974 million shares [1] - Yongxin Zhicheng: Qian'an Venture Capital has cumulatively reduced its stake by 3.7% [1] Other Notable Events - Fusenmei: Vice General Manager and Board Secretary Zhang Fengshu has been placed under investigation and detention measures [1] - *ST Dongtong: Company stock is suspended and may face delisting [1]

Core Points - Bid Pharma announced that its controlling shareholder, Dai Lan, holds 29,664,719 shares, accounting for 32.64% of the total shares [2] - Dai Lan plans to reduce her holdings by up to 148,835 shares, which represents 0.16% of the company's total share capital, within three months after the disclosure of the reduction plan [2] - The reduction will be executed through centralized bidding based on market conditions [2]

Core Points - Bid Pharma (688073) announced a plan for its controlling shareholder, Dai Lan, to reduce his stake in the company due to personal financial needs [1] - The reduction will occur within three months after the disclosure of the plan, with a maximum of 148,800 shares to be sold, representing 0.16% of the total share capital [1] - Dai Lan currently holds 29,664,700 shares, accounting for 32.64% of the total shares of Bid Pharma [1]

Core Viewpoint - Bid Pharma (688073.SH) announced that its controlling shareholder, actual controller, chairman, and general manager, Dai Lan, plans to reduce his shareholding within three months after the disclosure of the reduction plan, depending on market conditions [1] Summary by Sections - **Shareholding Reduction Plan** - Dai Lan intends to reduce his holdings through centralized bidding transactions, with a maximum reduction of 148,800 shares, which accounts for 0.16% of the company's total share capital [1] - The reduction price will be determined based on the market price at the time of the actual implementation [1]

Core Viewpoint - Bid Pharma announced that its controlling shareholder, Ms. Dai Lan, plans to reduce her shareholding in the company due to personal financial needs, with a maximum reduction of 148,835 shares, representing 0.16% of the total share capital [1] Group 1 - The reduction plan will commence 15 trading days after the announcement and will be executed within a three-month period [1] - The shares will be sold through centralized bidding on the market [1] - The selling price will be determined based on the market price at the time of the actual reduction [1]

Core Viewpoint - Bid Pharma (688073.SH) announced a plan for its controlling shareholder and actual controller, Dai Lan, to reduce his shareholding in the company due to personal funding needs [1] Group 1 - The reduction plan will be executed through centralized bidding transactions within three months after the disclosure of the reduction plan, starting from 15 trading days thereafter [1] - The maximum number of shares to be reduced is 148,800 shares, which accounts for no more than 0.16% of the company's total share capital [1] - The reduction price will be determined based on the market price at the time of the actual implementation [1]

Core Viewpoint - Bid Pharma (688073.SH) announced that its controlling shareholder, actual controller, and company chairman and general manager, Ms. Dai Lan, plans to reduce her shareholding due to personal funding needs, with a maximum reduction of 148,800 shares, accounting for 0.16% of the company's total share capital [1] Summary by Sections - Shareholding Reduction Plan - Ms. Dai Lan intends to reduce her shareholding through centralized bidding transactions starting 15 trading days after the announcement, within a period of three months [1] - The maximum number of shares to be reduced is 148,800, which represents 0.16% of the total share capital of the company [1] - The reduction price will be determined based on the market price at the time of the actual implementation [1]

上海毕得医药科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 证券代码：688073 证券简称：毕得医药 公告编号：2025-088 股东持股的基本情况 截至本公告披露之日，上海毕得医药科技股份有限公司（以下简称"毕得医 药"或"公司"）控股股东、实际控制人兼公司董事长、总经理戴岚女士持有公 司股份 29,664,719 股，占公司股份总数的 32.64%，其中 29,515,884 股为有限售 条件流通股，148,835 股为无限售条件流通股。 戴岚女士所持股份中，21,082,774 股来源为公司首次公开发行并上市前取得 的股份，8,433,110 股为前述股份因公司权益分派由资本公积转增取得的股份， 另外 148,835 股为集中竞价交易取得的股份。 减持计划的主要内容 因自身资金需要，戴岚女士计划根据市场情况拟于本减持计划披露之日起 15 个交易日后的 3 个月内通过集中竞价交易方式减持其通过二级市场集中竞价 交易取得的公司股份，减持数量不超过 14 ...